|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Te Li Chen | Te Li Chen | Byron Chao | 02-26558366 | 4F, No.3-2, Yuang St.Nangang DistrictTaipei City, Taiwan, R.O.C. | 2021/01/28 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | BioGend Therapeutics was established in July 2016 with a noble vision to develop regenerative bio-orthopedic medicine to advance the clinical science of maintaining healthy joints in the skeletal system. We are committed to developing innovative bio-orthopedic devices and treatment methods that can fulfill unmet clinical needs benefiting patients worldwide. The project management teams at BioGend Therapeutics are led by seasoned product development managers with team members from different functional areas. Each development project is carefully planned to follow the phase-gate process for effective and efficient execution. For highly regulated biomedical devices, the expertise in regulatory affairs and pre-clinical and clinical development is essential in order to gain regulatory approval and to realize the potential value of innovative bio-technologies. |
Market Information ( 2023/09/22 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
62 | 36.15 | 35.85 | 36.10 | 0.05 | 52 | N/A | N/A | ||||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2023/09/22) |
TPEx measures adopted (2023/09/22) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
![]() |
![]() |
![]() |